Erenumab (Aimovig) vs Rimegepant (Nurtec ODT)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP receptor · full Migraine pipeline

Erenumab (Aimovig)

Marketed by Amgen and partners

Approved in Migrainemonoclonal antibody
Reliable signal

NCT02456740 · Phase 3 · completed

The trial randomly assigned 955 participants to erenumab 70 mg, erenumab 140 mg, or placebo and used quadruple blinding during the 24-week placebo-controlled phase. The clinical primary endpoint, change in monthly migraine days, was significantly better with both erenumab doses than with placebo.

Next expected readout: July 2031 · NCT07655440 (registry estimate)

Reported efficacy

Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) (met)

Result source: NCT03867201

Rimegepant (Nurtec ODT)

Marketed by Pfizer and partners

Approved in Migrainesmall molecule
Reliable signal

NCT03235479 · Phase 3 · completed

This was a randomized, triple-masked, placebo-controlled trial with 1,162 randomized participants. Its two primary clinical endpoints were met: 2-hour pain freedom was 19.2% with rimegepant versus 14.2% with placebo (p=0.0298), and freedom from the most bothersome symptom was 36.6% versus 27.7% (p=0.0016).

Next expected readout: November 2026 · NCT06641466 (registry estimate)

Reported efficacy

Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) (met)

Result source: NCT05810038

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Erenumab (Aimovig)
Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18) NCT02456740 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change in monthly migraine days (last 4 of 12 weeks): erenumab 70 mg -6.64 and 140 mg -6.63 vs placebo -4.18; differences -2.46 (95% CI -3.52 to -1.39) and -2.45 (95% CI -3.51 to -1.38), both p<0.001 (CT.gov posted results). NCT02066415 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days at Week 12 (4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase): Placebo -1.84 migraine days / month (Standard Error 0.21) | Erenumab 70 mg QM -2.88 migraine days / month (Standard Error 0.21) NCT02483585 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45) NCT03867201 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Rimegepant (Nurtec ODT)
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase (OP and Weeks 9 to 12 of the DBT phase): Rimegepant - Randomization Phase -4.3 Total Migraine Days per Month (95% CI -4.83 to -3.87) | Placebo - Randomization Phase -3.5 Total Migraine Days per Month (95% CI -4 to -3.04) NCT03732638 · Phase 2/3 · design grade: moderate · reviewed ClinicalTrials.gov result
Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) NCT05810038 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91) NCT05399485 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Erenumab (Aimovig)'s landscape · Rimegepant (Nurtec ODT)'s landscape